Patents by Inventor Karen Morrison
Karen Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10918735Abstract: The synthesis of various pyrazino[1?,2?:1,5]pyrrolo[2,3-B]-indole-1,4-dione analogs has been successfully implemented in the present application. From these efforts, compounds having the structure of Formula I-a or Formula I-b: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, are provided herein. These biologically active derivatives have been used to effectively treat various diseases including cancer.Type: GrantFiled: March 5, 2019Date of Patent: February 16, 2021Assignees: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad Movassaghi, Justin Kim, Paul Hergenrother, Karen Morrison, Nicolas Boyer
-
Publication number: 20190255187Abstract: The synthesis of various pyrazino[1?,2?:1,5]pyrrolo[2,3-b]-indole-1,4-dione analogs has been successfully implemented in the present application. From these efforts, compounds having the structure of Formula I-c: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R4-R8, R3?, R6?, and n are as defined herein, are provided. These biologically active derivatives have been further used to prepare cell-specific drug conjugates effective in treating various diseases including cancer.Type: ApplicationFiled: March 5, 2019Publication date: August 22, 2019Applicants: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad Movassaghi, Justin Kim, Paul Hergenrother, Karen Morrison, Nicholas Boyer
-
Patent number: 10220099Abstract: The synthesis of various pyrazino[1?,2?:1,5]pyrrolo[2,3-b]-indole-1,4-dione analogs has been successfully implemented in the present application. From these efforts, compounds having the structure of Formula I-c: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R4-R8, R3?, R6?, and n are as defined herein, are provided. These biologically active derivatives have been further used to prepare cell-specific drug conjugates effective in treating various diseases including cancer.Type: GrantFiled: May 10, 2016Date of Patent: March 5, 2019Assignees: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad Movassaghi, Justin Kim, Paul J. Hergenrother, Karen Morrison, Nicolas Boyer
-
COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES
Publication number: 20160354483Abstract: The present application provides, among other things, compounds, compositions and methods for treating various diseases including cancer.Type: ApplicationFiled: May 10, 2016Publication date: December 8, 2016Applicants: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad Movassaghi, Justin Kim, Paul J. Hergenrother, Karen Morrison, Nicolas Boyer -
Patent number: 9353150Abstract: The present application provides, among other things, a compound of Formula I-a and/or I-b, or a pharmaceutically acceptable salt thereof, wherein the variables are defined in the specification. The compounds of the invention are useful for treating various diseases including cancer.Type: GrantFiled: December 4, 2013Date of Patent: May 31, 2016Assignees: Massachusetts Institute of Technology, The Board of Trustees of the University of IllinoisInventors: Mohammad Movassaghi, Justin Kim, Paul J. Hergenrother, Karen Morrison, Nicolas Boyer
-
Publication number: 20070212299Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.Type: ApplicationFiled: January 19, 2007Publication date: September 13, 2007Applicant: AGENSYS, INC.Inventors: Aya Jakobovits, Arthur Raitano, Mary Faris, Rene Hubert, Wangmao Ge, Karen Morrison, Robert Morrison, Pia Challita-Eid
-
Publication number: 20070160530Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits issue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.Type: ApplicationFiled: October 19, 2006Publication date: July 12, 2007Inventors: Aya Jakobovits, Soudabeh Etessami, Pia Challita-Eid, Juan Perez-Villar, Karen Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur Raitano
-
Publication number: 20070053921Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.Type: ApplicationFiled: September 8, 2006Publication date: March 8, 2007Inventors: Arthur Raitano, Karen Morrison, Wangmao Ge, Pia Challita-Eid, Aya Jakobovits
-
Publication number: 20070054284Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.Type: ApplicationFiled: March 2, 2006Publication date: March 8, 2007Applicant: Agensys, Inc.Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Karen Morrison, Robert Morrison, Wangmao Ge, Aya Jakobovits
-
Publication number: 20070048299Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.Type: ApplicationFiled: June 17, 2005Publication date: March 1, 2007Applicant: AGENSYS, INC.Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
-
Publication number: 20070048283Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.Type: ApplicationFiled: June 15, 2005Publication date: March 1, 2007Applicant: AGENSYS, INC.Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
-
Publication number: 20070041968Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.Type: ApplicationFiled: June 17, 2005Publication date: February 22, 2007Applicant: AGENSYS, INC.Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
-
Publication number: 20070004913Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: ApplicationFiled: June 2, 2004Publication date: January 4, 2007Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Karen Morrison, Aya Jakobovits
-
Publication number: 20060275211Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.Type: ApplicationFiled: March 31, 2006Publication date: December 7, 2006Applicant: Agensys, Inc.Inventors: Aya Jakobovits, Steven Kanner, Pia Challita-Eid, Juan Perez-Villar, Daulet Satpaev, Arthur Raitano, Robert Morrison, Karen Morrison, Xiao-Chi Jia, Jean Gudas
-
Publication number: 20060002993Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: ApplicationFiled: June 2, 2004Publication date: January 5, 2006Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Karen Morrison, Aya Jakobovits
-
Publication number: 20050265924Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: ApplicationFiled: April 1, 2005Publication date: December 1, 2005Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Karen Morrison, Aya Jakobovits
-
Publication number: 20050221400Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: ApplicationFiled: May 17, 2005Publication date: October 6, 2005Applicant: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-Chi Jia, Robert Morrison, Karen Morrison, Hui Shao, Pia Challita-Eid, Arthur Raitano
-
Publication number: 20050214211Abstract: A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization.Type: ApplicationFiled: March 3, 2005Publication date: September 29, 2005Inventors: Pia Challita-Eid, Arthur Raitano, Mary Faris, Rene Hubert, Steven Mitchell, Daniel Afar, Douglas Saffran, Karen Morrison, Robert Morrison, Wangmao Ge, Aya Jakobovits
-
Publication number: 20050208039Abstract: A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.Type: ApplicationFiled: February 10, 2004Publication date: September 22, 2005Applicant: AGENSYS, INC.Inventors: Aya Jakobovits, Robert Morrison, Arthur Raitano, Pia Challita-Eid, Juan Perez-Villar, Karen Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven Kanner
-
Publication number: 20050086707Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.Type: ApplicationFiled: June 4, 2004Publication date: April 21, 2005Inventors: Aya Jakobovits, Soudabeh Etessami, Pia Challita-Eid, Juan Perez-Villar, Karen Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur Raitano